Wockhardt Ltd is exiting its loss-making US generics business, as it focuses on its new antibiotics drug discovery and insulin portfolios. The drugmaker said on Friday that it has made a Chapter 7 ...

Indian pharma major Wockhardt is set to announce a major production deal for an undisclosed vaccine. The formal announcement is due in two weeks and the production of the vaccine will begin in October ...

Habil F Khorakiwala, Founder and Chairman of the Wockhardt Group, said the company has around ₹1,700 crore in debt but has no ...

In the summer of 2013, Wockhardt Chairman Habil Khorakiwala had finally begun to breathe easy after five years of losses, asset sales, court cases and corporate-debt restructuring. During an ...

Wockhardt on Friday said that it will exit from the US generic drug market, marking a significant shift in its business direction. The move comes after years of sustained losses in the segment, with ...